Astellas Pharma Gmbh

Takeda Pharmaceutical Company Limited

Tomoyoshi Imaizumi

Ryo Sato

Susumu Yamaki

Kazuyuki Kuramoto

Shigeki Kunikawa

Takanori Koike

Itsuro Shimada

Tomoaki Abe

Kazushi Watanabe

Jiro Fujiyasu

Takahiro Nigawara

Michinori Akaiwa

Keisuke Arakawa

Takanobu Araki

Yoshiki Satake

Satoshi Sasamura

Masashi Shimazaki

Tomohki Satou

Takeyuki Nagashima

Takahiro Morikawa

Naoyuki Masuda

Eiji Kawaminami

Kenichi Kawaguchi

Kazuhiko Ohne

Hisao Hamaguchi

Sunao Imada

Masataka Morita

Yohei Seki

Toru Asano

Ikumi Kuriwaki

Yasuharu Urano

Takeshi Hondo

Keisuke Matsuura

Mitsuaki Okumura

Shimpei Kawakami

Hiroki Fukudome

Kohei Inamura

Hideyuki Watanabe

Hiroki Ishioka

Osamu Kaneko

Junko Yarimizu

Tomohiro Yoshinari

Yuka Koike

[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.

Quinazoline compound for inducing degradation of G12D mutant KRAS protein

[Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Quinazoline compound

Compounds of formula (I) defined herein are useful as a dopamine D1 receptor positive allosteric modulators (D1 PAM) and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like.

Imidazodiazepine compound

[Problem] To provide a compound which is useful as an agent for preventing and/or treating kidney diseases. [Means for Solution] The present inventors have studied compounds having a trypsin inhibitory activity, and have confirmed that a guanidinobenzoic acid ester compound has a trypsin inhibitory activity, thereby completing the present invention. The guanidinobenzoic acid ester compound of the present invention can be used as an agent for preventing and/or treating kidney diseases (for example, chronic kidney disease, acute glomerulonephritis, acute kidney injury, and the like) as an agent which will substitute low-protein diet therapy, and/or as an agent for preventing and/or treating trypsin-related diseases (for example, chronic pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like).

Guanidinobenzoic acid ester compound

[Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.

Guanidinobenzoic acid compound

Growing community of inventors

Tokyo, Japan

Tomoyoshi Imaizumi